Renal pelvis cancer | Where are the weaknesses and symptoms of cancer cells? | Increase survival rate | Ureter cancer | Ttransitional cell cancer | Stage | Stage 0 | Stage 1 | Stage 2 | Stage 3 | Stage 4
Best adjuvant (assist) for chemotherapy | 1+1>487% |
Kidney cancer can develop in adults and children. The main types of kidney cancer are renal cell cancer, transitional cell cancer, and Wilms tumor. Certain inherited conditions increase the risk of kidney cancer. Explore the links on this page to learn more about kidney cancer treatment, statistics, research, and clinical trials.
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
survival rate | cancer | Contents survival rate | cancer | Etymology and definitions survival rate | cancer | Signs and symptoms survival rate | cancer | Local symptoms survival rate | cancer | Systemic symptoms survival rate | cancer | Metastasis survival rate | cancer | Causes survival rate | cancer | Chemicals survival rate | cancer | Diet and exercise survival rate | cancer | Infection survival rate | cancer | Radiation survival rate | cancer | Heredity survival rate | cancer | Physical agents survival rate | cancer | Hormones survival rate | cancer | Autoimmune diseases survival rate | cancer | Pathophysiology survival rate | cancer | Genetics survival rate | cancer | Epigenetics survival rate | cancer | Metastasis survival rate | cancer | Metabolism survival rate | cancer | Diagnosis survival rate | cancer | Classification survival rate | cancer | Prevention survival rate | cancer | Dietary survival rate | cancer | Medication survival rate | cancer | Vaccination survival rate | cancer | Screening survival rate | cancer | Recommendations survival rate | cancer | Genetic testing survival rate | cancer | Management survival rate | cancer | Cancer survival rate | cancer | Radiation survival rate | cancer | Surgery survival rate | cancer | Palliative care survival rate | cancer | Immunotherapy survival rate | cancer | Laser therapy survival rate | cancer | Alternative medicine survival rate | cancer | Prognosis survival rate | cancer | Epidemiology survival rate | cancer | History survival rate | cancer | Society and culture survival rate | cancer | Economic effect survival rate | cancer | Workplace survival rate | cancer | Research survival rate | cancer | Pregnancy survival rate | cancer | Other animals survival rate | cancer | Notes survival rate | cancer | Further reading survival rate | cancer | External links Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Contents Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Etymology and definitions Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Signs and symptoms Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Local symptoms Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Systemic symptoms Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Metastasis Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Causes Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Chemicals Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Diet and exercise Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Infection Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Radiation Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Heredity Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Physical agents Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Hormones Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Autoimmune diseases Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Pathophysiology Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Genetics Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Epigenetics Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Metastasis Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Metabolism Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Diagnosis Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Classification Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Prevention Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Dietary Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Medication Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Vaccination Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Screening Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Recommendations Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Genetic testing Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Management Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Chemotherapy Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Radiation Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Surgery Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Palliative care Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Immunotherapy Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Laser therapy Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Alternative medicine Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Prognosis Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Epidemiology Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | History Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Society and culture Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Economic effect Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Workplace Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Research Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Pregnancy Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Other animals Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Notes Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | Further reading Renal pelvis cancer | Ureter cancer | Ttransitional cell cancer | survival rate | External links